

# Scientific Sessions at a Glance



# 85<sup>TH</sup> SCIENTIFIC SESSIONS

## Outcome & Innovation Highlights

**Chicago**  
Illinois

**June**  
20-23

**12,699**  
Total Attendees

From **102**  
Countries

**900**  
Speakers

**15**  
Press Releases

**~20,000**  
News Placements

**150**  
Exhibitors



With dynamic discussions spanning fundamental science to late-breaking clinical trials, this meeting is an unparalleled opportunity to connect, learn, and help drive what's next in diabetes."

**Marlon Pragnell, PhD**  
ADA Vice President of  
Research & Science



### From Standards of Care to Standards of Practice

The 2025 *Standards of Care in Diabetes* includes all of current clinical practice recommendations of the American Diabetes Association® (ADA).

Pharmacological and technological advances drove many of this year's changes to topics that included:

- Glucose-Lowering Pharmacotherapy
- Diabetes Technology
- Care for Older Adults
- Care for Pregnancy
- Population Health
- Inpatient and DKA
- Improving Health Outcomes



### First ADA Guidelines on Liver Disease in Diabetes

A dual glucose-dependent insulinotropic polypeptide /glucagon-like peptide-1 receptor agonist (GLP-1 RA) is one recommendation for treatment.

### Benefits & Barriers in Therapies for Chronic Kidney Disease & Diabetes


GLP-1 RAs, non-steroidal mineralocorticoid antagonists, and sodium glucose cotransporter-2 inhibitors bring transformative benefits.

### New GLP-1 Therapies Enhance Quality of Weight Loss

Two groundbreaking studies have found the potential for muscle mass preservation in patients undergoing obesity treatment therapy.

### Artificial Intelligence Models Detect Type 1 Diabetes Risk Before Clinical Onset

With greater accuracy and fewer false positives than standard screening methods, this model can help patients prepare for their future.



### Highlighting First ADA Standards of Care for Overweight and Obesity

The first two chapters have been released, with the remainder to be published later this year.

Chapter 1, **Introduction and Methodology** gives an overview of the challenges associated with this chronic disease, and chapter 2, **Weight Stigma and Bias**, addresses how health care professionals can create inclusive clinical environments to improve obesity care.

Years of research and clinical trials have resulted in many opportunities for improved obesity care, including new approaches to weight loss, treatments such as GLP-1 RAs, surgeries, and procedures, but provider education remains a major challenge.



### Once-Weekly Insulin Achieves Comparable A1C Reduction to Daily Insulin Therapy

In QWINT-1 trial, patients treated with once-weekly insulin achieved an average **A1C of 6.92%**—results in line with the daily therapy A1C of 6.96%.

### Continuous Glucose Monitor (CGM) Insights

CGM data can be used to:

- Avoid diabetes-related ketoacidosis
- Measure the burden of hypoglycemia
- Deliver precise diabetes care



### Oral Semaglutide Has Positive CV Benefits in Type 2 Diabetes

People living with type 2 diabetes and high cardiovascular (CV) disease risk saw a **14% reduction** in major adverse CV events in global SOUL trial.

## Read more at [ADAMeetingNews.org](https://ADAMeetingNews.org)

Save the Date for the 86<sup>TH</sup> Scientific Sessions in New Orleans: June 5-8, 2026